(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 6 May 2005 (06.05.2005)

(10) International Publication Number WO 2005/040831 A1

(51) International Patent Classification7: C12Q 1/68

G01N 33/68,

(21) International Application Number:

PCT/EP2004/011632

(22) International Filing Date: 15 October 2004 (15.10.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

03023815.8

17 October 2003 (17.10.2003)

- (71) Applicants (for all designated States except US):
- (71) Applicants (for all designated States except US):
 DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
 [DE/DE]; Im Neuenheimer Feld 280, 69120 Heidelberg
 (DE). RUBRECHT-KARLS-UNIVERSITÄT HEIDELBERG [DE/DE]; Grabengasse 1, 69117 Heidelberg
 (DE).

 (72) Inventors; and
 (75) Inventors/Applicants (for US only): GACK, Sablne
 [DE/DE]; Schönauer Strasse 23, 68723 Plankstadt (DE).
 SCHORPP-KISTNER, Marlna [DE/DE]; Weidenweg
 4, 76448 Durmersheim (DE). ANGEL, Peter [DE/DE];
 Am Hang 7, 69181 Leimen (DE). WROBEL, Gunnar
 [DE/DE]; Römerstrasse 18, 69115 Heidelberg (DE).

 LICHTER, Peter [DE/DE]; Am Grossen Wald 36,
 69251 Gaiberg (DE). MARME, Alexander [DE/DE];
 Friedrich-Ebert-Anlage 23, 69117 Heidelberg (DE).

 (57) Abstract: The present invention relates to the significant role
 related disorders. The invention further relates to the use of said g
 of activity of the gene products in diagnosis and treatment of prese

STUMM, Susanne [DE/DE]; Hauprstrasse 11, 69181 Leimen (DE).

- (74) Agent: HUHN, Michael; Isenbruck-Bösl-Hörschler-Wichmann-Huhn, Theodor-Heusse-Anlage 12, 68165 Mannheim (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF ADAM 12 FOR DIAGNOSIS AND THERAPY OF PREECLAMPSIA

(57) Abstract: The present invention relates to the significant role of ADAM 12, ADAM 12-L, and ADAM 12-S in preeclampsia and related disorders. The invention further relates to the use of said genes and gene products, ligands binding to those, and modulators of activity of the gene products in diagnosis and treatment of preeclampsia and related syndromes. The invention also relates to the use of further genes and combinations thereof in diagnosis of preeclampsia and related syndromes.

